RxDoctor Payments Data

Gerald Ahigian, MD

Family Medicine · Denver, NCNPI 1932154432

Payments from drug & device makers

$45,751in general payments, 2019–2025

Across 825 payments — averaging $55.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acella Pharmaceuticals, LLC$14K
  • Avion Pharmaceuticals$11K
  • Sanofi US Services Inc.$6K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Johnson & Johnson$888
  • plus $11K from 52 others

What the payments were for

  • Food & beverage$14,638100%
  • Education$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acella Pharmaceuticals, LLC7$14,471
Avion Pharmaceuticals2$11,050
Sanofi US Services Inc.3$5,569
AstraZeneca59$1,343
Novo Nordisk75$1,104
Johnson & Johnson42$888
Boehringer Ingelheim46$750
Mannkind Corporation35$734
Bayer44$669
Pfizer36$615
Kowa Pharmaceuticals America, Inc.34$613
Lilly USA, LLC39$607
Antares Pharma, Inc.29$597
Paratek Pharmaceuticals, Inc.26$520
Amgen29$469
Amarin Pharma, Inc.29$465
GSK14$386
Esperion Therapeutics, Inc.21$369
Merck24$347
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$325
Arbor Pharmaceuticals, Inc.18$315
Novartis15$274
Amneal Pharmaceuticals LLC16$273
Clarus Therapeutics Inc.11$268
AbbVie(2 entities)18$261
Azurity Pharmaceuticals, Inc.11$240
Sanofi-aventis U.S. LLC14$227
Takeda Pharmaceuticals U.S.A., Inc.12$201
Abbott9$189
Idorsia Pharmaceuticals US Inc9$178
IBSA Pharma Inc.10$162
Forte Bio-pharma LLC3$137
Tolmar, Inc.7$130
Biohaven Pharmaceutical Holding Company Ltd.4$89
Dexcom, Inc.4$88
Phathom Pharmaceuticals, Inc.5$80
Phadia US Inc.5$77
Renalytix AI, Inc.4$77
Nestle Healthcare Nutrition Inc.5$70
Astellas Pharma US Inc3$67
Sanofi Pasteur Inc.3$67
Romark Laboratories, LC2$46
Aytu Biopharma, Inc.2$39
Hikma Pharmaceuticals USA2$36
Almatica Pharma LLC2$33
Eisai Inc.2$32
E.r. Squibb & Sons, L.L.C.2$27
Intercept Pharmaceuticals, Inc.1$25
Cequr Corporation1$23
Sumitomo Pharma America, Inc.1$21
Currax Pharmaceuticals LLC1$16
Vistapharm, Inc.1$15
Zyla Life Sciences, Inc.1$15
Assertio Therapeutics, Inc.1$14
Pacira Therapeutics, Inc.1$13
Preventice Services, LLC1$12
Optinose US, Inc.1$12
Acerus Pharmaceuticals Corporation1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,751 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$75,241
Medicare patients
155
Services billed
7,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$81,332
EliquisApixaban65$71,986
XareltoRivaroxaban47$52,663
Tresiba Flextouch U-200Insulin Degludec26$37,988
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$24,251
MounjaroTirzepatide16$24,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$22,759
Synjardy XrEmpagliflozin/Metformin Hcl23$16,618
VascepaIcosapent Ethyl16$15,293
LinzessLinaclotide17$14,482
Xigduo XrDapaglifloz Propaned/Metformin14$10,751
Novolog FlexpenInsulin Aspart19$10,150
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen233$9,539
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,074
Omega-3 Acid Ethyl Esters55$5,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,104$81,33254 claims
PfizerEliquis$615$71,98665 claims
Johnson & JohnsonXarelto$888$52,66347 claims
Lilly USA, LLCMounjaro$607$24,01016 claims
GSKTrelegy Ellipta$386$22,75919 claims
Boehringer IngelheimSynjardy Xr$750$16,61823 claims
AbbVieLinzess$261$14,48217 claims
AstraZenecaBreztri Aerosphere$1,343$9,07414 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$273$4,186358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Denver

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →